Biotechnology

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

A new partnership is tackling a national skills gap by showing students the high-tech, world-changing reality of modern biomanufacturing. Here's how.

A Seattle biotech's award-winning vaccine for a deadly fever is now in human trials, powered by innovative tech that could change global vaccine deployment.

Pioneers of IVF technology are launching a clinical skincare program, aiming to merge cellular science with holistic patient support in fertility clinics.

Central Ohio cancer patients gain unprecedented access to advanced therapies and clinical trials as Zangmeister Cancer Center joins OSU's James Cancer Network.

With new CEO Andrew Zeringue, Theromics aims to tackle cancer recurrence with its HeatSYNC gel, a novel approach in the booming ablation market.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

A new partnership combines AI-driven precision with deep gene therapy expertise, aiming to overcome critical safety hurdles and redefine treatment for rare diseases.

A breakthrough NAMI microencapsulation tech ensures probiotics survive stomach acid, promising a new standard of health and wellness for cats and dogs.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

A landmark advocacy effort secures official recognition for clinical research professionals, shining a light on a workforce facing critical shortages and burnout.

The wellness brand is shifting gut care from a quick fix to a daily ritual with a new product line and a savvy digital strategy targeting modern consumers.

A year-long Texas trial shows a new biosurfactant boosts oil recovery by 15% with a massive ROI, signaling a major shift in fracking chemistry.

With its latest purchase, Harbor IT expands into the Southeast, targeting life sciences and manufacturing with a highly specialized service model.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

With a new CCO and advanced T-Body™ platform, Invenra is shifting from R&D to aggressive commercialization. Can it dominate the multispecific antibody market?